Roche keeps 2026 outlook as Q3 sales rise 7% at constant currencies

What happened: Roche kept its full-year outlook unchanged after third-quarter sales rose 7% at constant currencies, helped by demand for multiple sclerosis, eye and allergy drugs. Key numbers: Q3 sales rose 8% in Swiss francs. Nine-month group sales rose 6% at constant rates to CHF 46.49 billion, but 1% in francs. Why it matters: Roche still expects 2026 group sales to grow mid single digit at constant rates and core EPS high single digit, and expects to raise its dividend in Swiss francs again. The stronger franc against the dollar cut reported results.

Roche kept its full-year outlook unchanged after third-quarter sales rose 7% at constant currencies, helped by demand for multiple sclerosis, eye and allergy drugs.

Roche still expects 2026 group sales to grow mid single digit at constant rates and core EPS high single digit, and expects to raise its dividend in Swiss francs again. The stronger franc against the dollar cut reported results.